Posted by Michael Wonder on 13 Nov 2016
Highlights from CHMP November 2016 meeting
11 November 2016 - Nine medicines recommended for approval, including three biosimilars.
The EMA's CHMP recommended nine medicines for approval at its November 2016 meeting.
The CHMP recommended granting a marketing authorisation for Afstyla (lonoctocog alfa) for the prevention and treatment of bleeding in patients with haemophilia A.
Vemlidy (tenofovir alafenamide fumarate) received a positive opinion from the CHMP for the treatment of chronic hepatitis B.
Fiasp (insulin aspart) was recommended for approval by the CHMP for the treatment of diabetes.
Suliqua (insulin glargine with lixisenatide) was recommended for approval for the treatment of type 2 diabetes.
